Financhill
Buy
61

RLMD Quote, Financials, Valuation and Earnings

Last price:
$4.60
Seasonality move :
6.09%
Day range:
$4.33 - $4.75
52-week range:
$0.24 - $5.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
35.64x
Volume:
335.4K
Avg. volume:
1.2M
1-year change:
1172.83%
Market cap:
$337.3M
Revenue:
--
EPS (TTM):
-$1.80

Earnings Data

Next earnings date for RLMD
Mar 26
2026
Most recent earnings per share
-$0.30
Missed by $0.30
(Nov 13/2025)
Consensus Estimate
--
(Nov 13/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

RLMD Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
03/26/2026 Q4 -- -- -- -- --
11/13/2025 Q3 -- -- -$0.30 -- --
08/07/2025 Q2 -- -- -$0.30 -- --
05/12/2025 Q1 -- -- -$0.58 -- --
03/27/2025 Q4 -- -- -$0.62 -- --
11/07/2024 Q3 -- -- -$0.72 -- --
08/07/2024 Q2 -- -- -$0.59 -- --
05/08/2024 Q1 -- -- -$0.72 -- --
03/19/2024 Q4 -- -- -$0.83 -- --
11/08/2023 Q3 -- -- -$0.73 -- --
08/08/2023 Q2 -- -- -$0.84 -- --
05/11/2023 Q1 -- -- -$0.87 -- --
03/23/2023 Q4 -- -- -$1.26 -- --
11/10/2022 Q3 -- -- -$1.31 -$1.47 $0.16
08/11/2022 Q2 -- -- -$1.33 -$1.32 -$0.01
05/05/2022 Q1 -- -- -$1.40 -$1.22 -$0.18
03/23/2022 Q4 -- -- -$1.80 -$1.88 $0.08
11/11/2021 Q3 -- -- -$2.44 -$1.55 -$0.89
08/10/2021 Q2 -- -- -$1.56 -$1.47 -$0.09
05/12/2021 Q1 -- -- -$1.34 -$1.42 $0.08
03/23/2021 Q4 -- -- -$1.29 -$1.31 $0.01
11/12/2020 Q3 -- -- -$1.05 -$0.94 -$0.11
08/12/2020 Q2 -- -- -$0.73 -$0.63 -$0.11
05/15/2020 Q1 -- -- -$0.72 -$0.37 -$0.35
12/31/2019 Q4 -- -- -$0.39 -- --
09/30/2019 Q3 -- -- -$0.38 -- --

Relmada Therapeutics, Inc. Earnings Questions

  • How Much did Relmada Therapeutics, Inc. Generate in Revenue Last Quarter?

    Relmada Therapeutics, Inc. reported -- worth of top line sales in its most recent quarter.

  • Did Relmada Therapeutics, Inc. Beat Earnings Last Quarter?

    Relmada Therapeutics, Inc. announced earnings per share of -$0.30 which represents a miss of analyst forecast a -- per share.

  • Is Relmada Therapeutics, Inc. Profitable?

    Relmada Therapeutics, Inc. reported -- that represents -- per share over the last quarter.

  • What is the Analyst Consensus for Relmada Therapeutics, Inc. EPS Next Year?

    Relmada Therapeutics, Inc.'s earnings are forecast to decrease from -$2.65 per share to -$1.72 per share next year representing a decrease of -68.7%.

  • When is Relmada Therapeutics, Inc.'s Earnings Date?

    Relmada Therapeutics, Inc.'s next earnings date is March 26, 2026.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
57
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
80
TVTX alert for Dec 25

Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.

Buy
68
KOD alert for Dec 25

Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.

Buy
64
ZCSH alert for Dec 25

Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock